Trinidad and Tobago vs Uruguay: Measles-containing-vaccine second-dose (MCV2) immunization coverage
Trinidad and Tobago
96.0%
in 2025
Uruguay
95.0%
in 2025
Trinidad and Tobago rank
26th
Uruguay rank
29th
Measles-containing-vaccine second-dose (MCV2) immunization coverage over time
- Trinidad and Tobago
- Uruguay
How they compare
Trinidad and Tobago currently reports 96.0% against 95.0% in Uruguay, a difference of 1.0%.
The two have swapped places 7 times across 26 shared years of data; in 2000 it was Uruguay ahead.
Trinidad and Tobago ranks 26th and Uruguay ranks 29th of 194 countries.
Trinidad and Tobago has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Trinidad and Tobago | Uruguay | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 71.8% | 0.0% | 71.8% | Trinidad and Tobago |
| 2010s | 85.6% | 65.2% | 20.4% | Trinidad and Tobago |
| 2020s | 91.0% | 90.8% | 0.2% | Trinidad and Tobago |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher measles-containing-vaccine second-dose (mcv2) immunization coverage, Trinidad and Tobago or Uruguay?
- Trinidad and Tobago, at 96.0% against 95.0% in Uruguay as of 2025.
- What is the difference in measles-containing-vaccine second-dose (mcv2) immunization coverage between Trinidad and Tobago and Uruguay?
- 1.0%, with Trinidad and Tobago ahead.
- How many years of comparable data are there for Trinidad and Tobago and Uruguay?
- 26 years are reported by both, from 2000 to 2025.
- How do Trinidad and Tobago and Uruguay rank globally for measles-containing-vaccine second-dose (mcv2) immunization coverage?
- Trinidad and Tobago ranks 26th and Uruguay ranks 29th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Measles-containing-vaccine second-dose (MCV2) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.